UNITED KINGDOM – AstraZeneca has announced that it would pay Ionis Pharmaceuticals, the market leader in RNA-targeted therapies, US$200 million for the rights to its investigational medicine, eplontersen. Eplontersen is…
Read MoreAstraZeneca pumps US$ 200 million to acquire rights into Ionis’ rare disease drug
